




Europäisches  
Patentamt

European  
Patent Office

Office européen  
des brevets

*Handwritten signature*



Bescheinigung

Certificate

Attestation

Die angehefteten Unterla-  
gen stimmen mit der  
ursprünglich eingereichten  
Fassung der auf dem näch-  
sten Blatt bezeichneten  
europäischen Patentanmel-  
dung überein.

The attached documents  
are exact copies of the  
European patent application  
described on the following  
page, as originally filed.

Les documents fixés à  
cette attestation sont  
conformes à la version  
initialement déposée de  
la demande de brevet  
européen spécifiée à la  
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

02026165.7

**PRIORITY DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH  
RULE 17.1(a) OR (b)

Der Präsident des Europäischen Patentamts;  
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets  
p.o.

*Handwritten signature of R C van Dijk*

R C van Dijk

Best Available Copy



Anmeldung Nr:  
Application no.: 02026165.7  
Demande no:

Anmeldetag:  
Date of filing: 25.11.02  
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

Octapharma AG  
Seidenstrasse 2  
8853 Lachen  
SUISSE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:  
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.  
If no title is shown please refer to the description.  
Si aucun titre n'est indiqué se référer à la description.)

Prekallikrein depleted plasma derived albumin fraction

In Anspruch genommene Priorität(en) / Priority(ies) claimed /Priorité(s)  
revendiquée(s)  
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/  
Classification internationale des brevets:

A61K/

Am Anmeldetag benannte Vertragsstaaten/Contracting states designated at date of  
filing/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

Prekallikrein depleted plasma derived albumin fraction

The present invention pertains to a method of manufacturing an albumin enriched fraction having a reduced prekallikrein activator (PKA) and an albumin containing fraction having a reduced prekallikrein activator (PKA) obtainable according to the method of the invention.

Albumin containing preparations are used as infusion solutions for patients who are in need thereof. In order to have a more physiological environment liquid substitution is infused into patients containing not only salts in physiological concentration but also albumin as extender. Albumin preparations may contain prekallikrein activator, which may lead to unwanted side effects, which may be due to interference of the prekallikrein activator in the renin-angiotensin system.

The object of the present invention was to reduce the PKA content in plasma derived fractions containing albumin. It was another object to provide an albumin containing fraction having a reduced PKA value.

The object was solved by a method of manufacturing an albumin enriched fraction having a reduced prekallikrein activator (PKA) comprising the steps of:

- (a) reconstitution of paste V, (Cohn fractionation)
- (b) performing a concentration step of the fraction obtained in step (a),
- (c) heating the fraction obtained in step (b) in a range of from 50 °C to 70 °C for a sufficient time to pasteurize the fraction, and
- (d) optionally filling of the obtained fraction for use.

In an embodiment of the present invention a second pasteurisation step is performed after filling.

In particular, the incubation step is performed at 50 to 70 °C for duration of at least 5 hours, in particular 10 hours.

Starting with reconstitution of paste V and optionally addition of filter aids a filtration is performed preferably with a filter having a pore size of about 0.2  $\mu\text{m}$ . If necessary, a pH adjustment has to be performed. The pH should be in the range of 7.2 - 7.6. Typically an ultrafiltration to 8 % (w/v) protein content is performed followed by diafiltration and another ultrafiltration for concentration of the protein. This leads to protein concentrations of at least 20 %.

5 Then another filtration may be performed preferably with a membrane having a pore size of about 0.2  $\mu\text{m}$ .

Stabilizers are added for example 0.08 mmol/g albumin each of N-acetyl-DL-tryptophan and sodium caprylate, which is followed by a further pH adjustment in a range of 6.7 to 7.3. Adjustment of protein and sodium content is achieved and a bulk pasteurization is performed preferably in a range of 58 °C to 65 °C for at least 9 hours. This step is followed by a sterile filtration. The sample is stored less than 2 weeks at 2 °C to 25 °C. The albumin sterile bulk is

10 subjected to a further terminal sterile filtration and filled. After the filling a second pasteurization step under similar conditions as described before can be performed. A further incubation step may be added. After visual inspection the preparation is ready for storage and administration.

The method of the invention also provides an albumin containing fraction

20 having a reduced prekallikrein activator (PKA).

The PKA content of the albumin of the invention is less than 12 IU/ml, preferably 10 IU/ml, wherein the PKA is determined according to European Pharmacopoeia, Fourth Edition, 2.6.15, p.147-148.

The invention is further described by the following non-limiting examples.

## 25 Examples

### Example 1:

The paste V is suspended in the 1.6 fold of its weight of water for injections for > 6 hours at  $-2 \pm 2$  °C. Filter aids are added to the product and the preparation is stirred for 30 min. The depth filter is prewashed with water for injections and

30 subsequently with 10% (v/v) ethanol. The solution is clarified by passing through

- 3 -

the depth filter and a subsequent 0.2  $\mu\text{m}$  membrane filter. The filter is post-washed with 10% ethanol in water for injections. The pH is adjusted to  $7.4 \pm 0.2$  with 3 M sodium hydroxide solution.

5 A protein concentration of 8 % is obtained by ultrafiltration through membranes with an exclusion limit of 10 kDalton. The concentrate is diafiltered against a  $\geq 3$  fold quantity of 0.5 M sodium chloride solution, followed by a  $\leq 3$  fold quantity of water for injections. After the diafiltration, the albumin solution is concentrated to a protein concentration of approximately 22% by ultrafiltration at  $\leq +15^\circ\text{C}$ . The solution is clarified by passing through the depth filter and a subsequent 0.2  $\mu\text{m}$  membrane filter. The depth filter is prewashed with water for injections

10 Subsequently 0.0106 g caprylic acid/g protein and 0.0182 g N-acetyl-DL-tryptophan/g protein are dissolved in 10% (w/v) sodium hydroxide and added to the albumin solution under slow stirring. The pH is adjusted to  $7.0 \pm 0.3$ . The albumin solution is adjusted to a protein concentration of  $200 \pm 10\text{g/l}$  by adding

15 water for injections. The sodium content is adjusted to  $150 \pm 7.5\text{mmol/l}$  by adding sodium chloride. The solution is agitated for at least 9 hours at  $58 - 65^\circ\text{C}$ . The albumin solution is sterile filtered through a sterilising grade filter membrane of a nominal pore size of typically 0.2  $\mu\text{m}$ . The sterile filter is tested for integrity before and after use by an appropriate test method as

20 recommended by the specification of the manufacturer. The sterile filtered albumin is stored at  $+2^\circ\text{C} - +25^\circ\text{C}$  not longer than 2 weeks. The sterile solution is filled using a terminal 0.2  $\mu\text{m}$  sterile filter under aseptic conditions into depyrogenated infusion vials, which are closed with sterilised butyl-stoppers and sealed with aluminium caps. The sterile filter is tested for integrity before and after

25 use by an appropriate test method as recommended by the specification of the manufacturer. The filling volume is monitored throughout the filling process. Pasteurisation is done according European Pharmacopoeia. The final Containers are incubated according European Pharmacopoeia. Following the incubation period, all vials are visually inspected for particulate contamination, turbidity,

30 defects of vials and closures. Defective preparations are rejected. All vials are stored at  $+2^\circ\text{C}$  to  $+25^\circ\text{C}$ .

## Example 2:

The paste V is suspended in the 1.6 fold of its weight of water for injections for > 6 hours at  $-2 \pm 2^\circ\text{C}$ . Filter aids are added to the product and the preparation is stirred for 30 min. The depth filter is prewashed with water for injections and subsequently with 10% ethanol. The solution is clarified by passing through the depth filter and a subsequent  $0.2\ \mu\text{m}$  membrane filter. The filter is post-washed with 10% ethanol in water for injections. The pH is adjusted to  $7.4 \pm 0.2$  with 3 M sodium hydroxide solution. A protein concentration of 8 % is obtained by ultrafiltration through membranes with an exclusion limit of 10 kDalton. The concentrate is diafiltered against a  $\geq 3$  fold quantity of 0.5 M sodium chloride solution, followed by  $\leq 3$  fold quantity of water for injections. After the diafiltration, the albumin solution is concentrated to a protein concentration of approximately 26% by ultrafiltration at  $< +15^\circ\text{C}$ . The solution is clarified by passing through the depth filter and a subsequent  $0.2\ \mu\text{m}$  membrane filter. The depth filter is prewashed with water for injections. Subsequently 0.0106 g caprylic acid/g protein and 0.0182 g N-acetyl-DL-tryptophan/g protein are dissolved in 10% sodium hydroxide and added to the albumin solution under slow stirring. The pH is adjusted to  $7.0 \pm 0.3$ . The albumin solution is adjusted to a protein concentration of  $250 \pm 12\ \text{g/l}$  by adding water for injections. The sodium content is adjusted to  $150 \pm 7.5\ \text{mmol/l}$  by adding sodium chloride. The solution is agitated for at least 9 hours at  $58 - 65^\circ\text{C}$ . The albumin solution is sterile filtered through a sterilising grade filter membrane of a nominal pore size of typically  $0.2\ \mu\text{m}$ . The sterile filter is tested for integrity before and after use by an appropriate test method as recommended by the specification of the manufacturer. The sterile filtered albumin is stored at  $+2^\circ\text{C} - +25^\circ\text{C}$  not longer than 2 weeks. The sterile solution is filled using a terminal  $0.2\ \mu\text{m}$  sterile filter under aseptic conditions into depyrogenated infusion vials, which are closed with sterilised butyl-stoppers and sealed with aluminium caps. The sterile filter is tested for integrity before and after use by an appropriate test method as recommended by the specification of the manufacturer. The filling volume is monitored throughout the filling process. Pasteurisation is done according European Pharmacopoeia. The final Containers are incubated according European Pharmacopoeia. Following the incubation period,

- 5 -

all vials are visually inspected for particulate contamination, turbidity, defects of vials and closures. Defective preparations are rejected. All vials are stored at  $+2^{\circ}\text{C}$  to  $+25^{\circ}\text{C}$ .

Example 3:

5 The paste V is suspended in the 1.6 fold of its weight of water for injections for 6 hours at  $-2 \pm 2^{\circ}\text{C}$ . Filter aids are added to the product and the preparation is stirred for 30 min. The depth filter is prewashed with water for injections and subsequently with 10% ethanol. The solution is clarified by passing through the depth filter and a subsequent  $0.2\ \mu\text{m}$  membrane filter. The filter is post-washed  
10 with 10% ethanol in water for injections. The pH is adjusted to  $7.4 \pm 0.2$  with 3 M sodium hydroxide solution. A protein concentration of 8 % is obtained by ultrafiltration through membranes with an exclusion limit of 10 kDalton. The concentrate is diafiltered against a  $> 3$  fold quantity of 0.5 M sodium chloride solution, followed by a  $< 3$  fold quantity of water for injections. After the  
15 diafiltration, the albumin solution is concentrated to a protein concentration of approximately 22% by ultrafiltration less than  $+15^{\circ}\text{C}$ . The solution is clarified by passing through the depth filter and a subsequent  $0.2\ \mu\text{m}$  membrane filter. The depth filter is prewashed with water for injections. Subsequently 0.0106 g caprylic acid/g protein and 0.0182 g N-acetyl-DL-tryptophan/g protein are dissolved in 10%  
20 sodium hydroxide and added to the albumin solution under slow stirring. The pH is adjusted to  $7.0 \pm 0.3$ . The albumin solution is adjusted to a protein concentration of  $200 \pm 10\ \text{g/l}$  by adding water for injections. The sodium content is adjusted to  $150 \pm 7.5\ \text{mmol/l}$  by adding sodium chloride. The solution is agitated for at least 10 hours at  $58 - 65^{\circ}\text{C}$ . The albumin solution is  
25 sterile filtered through a sterilising grade filter membrane of a nominal pore size of typically  $0.2\ \mu\text{m}$ . The sterile filter is tested for integrity before and after use by an appropriate test method as recommended by the specification of the manufacturer. The sterile filtered albumin is stored at  $+2^{\circ}\text{C}$  to  $+25^{\circ}\text{C}$  not longer than 2 weeks. The albumin solution is adjusted to a protein  
30 concentration of  $50 \pm 2.5\ \text{g/l}$  by adding water for injections. The pH is adjusted to  $7.0 \pm 0.3$ . The sodium content is adjusted to  $150 \pm 7.5\ \text{mmol/l}$  by adding of sodium chloride. The albumin solution is stored at  $+2^{\circ}\text{C}$  to  $+25^{\circ}\text{C}$

- 6 -

not longer than 24 hours until filling. The sterile solution is filled using a terminal 0.2  $\mu$ M sterile filter under aseptic conditions into depyrogenated infusion vials, which are closed with sterilised butyl-stoppers and sealed with aluminium caps. The sterile filter is tested for integrity before and after use by an appropriate test method as recommended by the specification of the manufacturer. The filling volume is monitored throughout the filling process. Pasteurization is done according European Pharmacopoeia. The final containers are incubated according to European Pharmacopoeia. Following the incubation period, all vials are visually inspected for particulate contamination, turbidity, defects of vials and closures. Defective preparations are rejected. All vials are stored at +2°C to +25°C.

#### Prekallikrein Activator

Prekallikrein activator (PKA) activates prekallikrein to kallikrein and may be assayed by its ability to cleave a chromophore from a synthetic peptide substrate so that the rate of cleavage can be measured spectrophotometrically and the concentration of PKA calculated by comparison with a reference preparation calibrated in International Units.

The International Unit is the activity of a stated amount of the International Standard which consists of freeze-dried prekallikrein activator. The equivalence in International Units of the International Standard is stated by the World Health Organization.

#### Preparation of prekallikrein substrate

To avoid coagulation activation, blood or plasma used for the preparation of prekallikrein must come into contact only with plastics or silicone-treated glass surfaces. Draw 9 volumes of human blood into 1 volume of anticoagulant solution (ACD, CPD or 38 g/l sodium citrate) to which 1 mg/ml of hexadimethrine bromide has been added. Centrifuge the mixture at 3600 g for 5 min. Separate the plasma and centrifuge again at 6000 g for 20 min to sediment platelets. Separate the platelet-poor plasma and dialyse against 10 volumes of buffer A for 20 h. Apply the dialysed plasma to a chromatography column containing agarose-DEAE for ion exchange chromatography which has



- 7 -

been equilibrated in buffer A and is equal to twice the volume of the plasma. Elute from the column with buffer A at 20 ml/cm<sup>2</sup> /h. Collect the eluate in fractions and record the absorbance at 280 nm (2.2.25). Pool the fractions containing the first protein peak so that the volume of the pool is about 1.2  
5 times the volume of the platelet-poor plasma.

Test the substrate pool for absence of kallikrein activity by mixing 1 part with 20 parts of the pre-warmed chromogenic substrate solution to be used in the assay and incubate at 37°C for 2 min. The substrate is suitable if the increase in absorbance is less than 0.001 per minute. Add to the pooled solution 7 g/l  
10 of sodium chloride and filter using a membrane filter (porosity 0.45 µm). Freeze the filtrate in portions and store at -25°C; the substrate may be freeze-dried before storage.

Carry out all procedures from the beginning of the chromatography to freezing in portions during a single working day.

#### 15 Assay

The assay is preferably carried out using an automated enzyme analyser at 37°C, with volumes, concentration of substrates and incubation times adjusted so that the reaction rate is linear at least up to 35 IU/ml. Standards, samples and prekallikrein substrate may be diluted as necessary using buffer B.

20 Incubate diluted standards or samples with prekallikrein substrate for 10 min such that the volume of the undiluted sample does not exceed 1/10 of the total volume of the incubation mixture to avoid errors caused by variation in ionic strength and pH in the incubation mixture. Incubate the mixture or a part thereof with at least an equal volume of a solution of a suitable synthetic  
25 chromogenic substrate, known to be specific for kallikrein (for example, N-benzoyl-L-prolyl-L-phenylalanyl-L-arginine 4-nitroanilide acetate R or D-prolyl-L-phenylalanyl-L-arginine-4-nitroanilide-dihydrochloride R), dissolved in buffer B. Record the rate of change in absorbance per minute for 2 min to 10 min at the wavelength specific for the substrate used. Prepare a blank for each  
30 mixture of sample or standard using buffer B instead of prekallikrein substrate.

- 8 -

Correct  $\Delta A/\text{min}$  by subtracting the value obtained for the corresponding blank. Plot a calibration curve using the values thus obtained for the reference preparation and the respective concentrations; use the curve to determine the PKA activity of the preparation to be examined.

## 5 Buffer A

Tris(hydroxymethyl)aminomethane	6.055 g
Sodium chloride	1.17 g
Hexadimethrine bromide	50 mg
Sodium azide	0.100 g

- 10 Dissolve the ingredients in water , adjust to pH 8.0 with 2 M hydrochloric acid and dilute to 1000 ml with water .

## Buffer B

Tris(hydroxymethyl)aminomethane	6.055 g
Sodium chloride	8.77 g

- 15 Dissolve the ingredients in water , adjust to pH 8.0 with 2 M hydrochloric acid and dilute to 1000 ml with water .

- 9 -

Production step	PKA value (according to the invention)	PKA value (comparative example)
After IPBP* and sterile filtration	3 IU/ml	n.a.**
After pasteurisation in final container	< 2 IU/ml	5 IU/ml
After incubation	4 IU/ml	18 IU/ml

Production step	PKA value (according to the invention)	PKA value (comparative example)
After IPBP* and sterile filtration	< 2 IU/ml	n.a.**
After pasteurisation in final container	< 2 IU/ml	2 IU/ml
After incubation	3 IU/ml	12 IU/ml

Production step	PKA value (according to the invention)	PKA value (comparative example)
After IPBP* and sterile filtration	< 2 IU/ml	n.a.**
After pasteurisation in final container	< 2 IU/ml	5 IU/ml
After incubation	2 IU/ml	20 IU/ml

\*IBPP in process bulk pasteurisation

5 \*\*n.a. not applicable

- 10 -

Claims

1. A method of manufacturing an albumin enriched fraction having a reduced prekallikrein activator (PKA) content comprising the steps of:
  - 5 (a) reconstitution of paste V (Cohn fractionation)
  - (b) performing a concentration step of the fraction obtained in step (a),
  - (c) heating the fraction obtained in step (b) in a range of from 50 °C to 70 °C for a sufficient time to pasteurise the fraction, and
  - (d) optionally filling of the obtained fraction for use.
- 10 2. The method of claim 1 wherein after filling a second pasteurisation step is performed.
3. The method of claim 1 and/or 2 wherein an incubating step is performed.
4. The method of claim 3 wherein the incubation step is performed under the following conditions for 10 days at 30 - 32 °C or 4 weeks at 20 - 25  
15 °C.
5. The method of any one of the claims 1 to 4 wherein the pasteurisation is performed for a time period of from at least 9 h at a temperature of 58 to 65 °C.
6. An albumin containing fraction having a reduced prekallikrein activator  
20 (PKA) obtainable according to the method of at least one of the claims 1 to 5.
7. The albumin of claim 6 having a PKA content of less than 12 IU/ml, preferably 10 IU/ml, wherein the PKA is determined according to European Pharmacopeia, Fourth Edition.

- 11 -

Abstract

An albumin containing fraction having a reduced prekallikrein activator (PKA) content and a method of manufacturing same comprising the steps of:

- 5 (a) reconstitution of paste V (Cohn fractionation),
- (b) performing a concentration step of the fraction obtained in step (a),
- (c) heating the fraction obtained in step (b) in a range of from 50 °C to 70 °C for a sufficient time to pasteurise the fraction, and
- (d) optionally filling of the obtained fraction for use.

10

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**